AbbVie’s lutikizumab meets primary endpoint in Phase 3 hidradenitis suppurativa trial
ABBV•AbbVie said its investigational lutikizumab met the primary goal in the Phase 3 INTREPID trial, improving clinical response versus placebo and reducing skin pain and disease flares. Additional data are expected in 2027 to support regulatory submissions in the second half of that year.
1. Trial results
AbbVie’s investigational lutikizumab met the primary goal in the Phase 3 INTREPID trial in adults and adolescents with moderate to severe hidradenitis suppurativa. Treatment improved clinical response versus placebo and reduced skin pain and disease flares, with no new safety concerns identified. Results will be presented at a future medical congress; additional trial data are expected in 2027 to support regulatory submissions in the second half of that year.
